SCHEMBL4087512 — predicted protein targets

Predicted protein targets (top 17)

	gene	UniProt	supporting neighbours	confidence
▸	EGFR	P00533	18/20	0.66

▸	GAK	O14976	1/20	0.64

▸	ALDH1A1	P00352	1/20	0.64

▸	FBP1	P09467	1/20	0.64

▸	MAPT	P10636	1/20	0.64

▸	ERBB2	P04626	5/20	0.62

▸	HDAC3	O15379	2/20	0.57

▸	HDAC4	P56524	2/20	0.57

▸	HDAC1	Q13547	2/20	0.57

▸	HDAC7	Q8WUI4	2/20	0.57

▸	HDAC2	Q92769	2/20	0.57

▸	HDAC10	Q969S8	2/20	0.57

▸	HDAC11	Q96DB2	2/20	0.57

▸	HDAC8	Q9BY41	2/20	0.57

▸	HDAC6	Q9UBN7	2/20	0.57

▸	HDAC9	Q9UKV0	2/20	0.57

▸	HDAC5	Q9UQL6	2/20	0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL12536553	1.00	EGFR (0.66)	EGFRGAKALDH1A1FBP1MAPT
SCHEMBL14489912	0.91	EGFR (0.72)	EGFRGAKALDH1A1FBP1MAPT
SCHEMBL29623598	0.91	EGFR (0.69)	EGFRGAKALDH1A1FBP1MAPT
SCHEMBL185131	0.91	EGFR (0.69)	EGFRGAKALDH1A1FBP1MAPT
SCHEMBL12536562	0.89	EGFR (0.66)	EGFRGAKALDH1A1FBP1MAPT
SCHEMBL14205022	0.89	EGFR (0.78)	EGFRERBB2
SCHEMBL14205852	0.89	EGFR (0.78)	EGFRERBB2
SCHEMBL3433430	0.89	EGFR (0.83)	EGFRERBB2
SCHEMBL1943518	0.89	EGFR (0.69)	EGFRGAKALDH1A1FBP1MAPT
SCHEMBL12754569	0.89	EGFR (0.67)	EGFRGAKALDH1A1FBP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20090312343-A1	QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS	HENNEQUIN LAURENT FRANCOIS AND	2009-12-17	—	—	US	disclosed
US-20090312343-A1	QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS	HENNEQUIN LAURENT FRANCOIS AND	2009-12-17	—	—	US	disclosed
US-20090312343-A1	QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS	HENNEQUIN LAURENT FRANCOIS AND	2009-12-17	—	—	US	disclosed
US-7569577-B2	Quinazoline derivatives as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2009-08-04	—	—	US	disclosed
US-7569577-B2	Quinazoline derivatives as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2009-08-04	—	—	US	disclosed
US-7569577-B2	Quinazoline derivatives as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2009-08-04	—	—	US	disclosed
EP-1667991-B1	QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2008-05-14	—	—	EP	disclosed
US-20070043009-A1	Quinazoline derivatives as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2007-02-22	—	—	US	disclosed
US-20070043009-A1	Quinazoline derivatives as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2007-02-22	—	—	US	disclosed
US-20070043009-A1	Quinazoline derivatives as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2007-02-22	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20090312343-A1	QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS	ERBB2, ABL1, EGFR	EGFR 3/4885GAK 112/4885ALDH1A1 3811/4885
US-20070043009-A1	Quinazoline derivatives as tyrosine kinase inhibitors	ERBB2, ABL1, EGFR	EGFR 3/4885GAK 131/4885ALDH1A1 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.